title: Complete response of esophageal small cell carcinoma amrubicin treatment.
abstract: Small cell carcinoma of the esophagus (SmCCE) is a rare and aggressive disease known to have a poor prognosis. SmCCE patients are generally treated with a chemotherapeutic regimen for small cell lung cancer. Salvage therapy for patients with relapsed or refractory tumors has not yet been established. A 63-year-old man with extensive SmCCE was treated with chemotherapy consisting of cisplatin (CDDP) and irinotecan (CPT-11). After the second course of CPT-11/CDDP, the celiac lymph node increased in size. Amrubicin (AMR) as second-line chemotherapy was started. The patient had a complete response after the fifth course of AMR, resulting in an 8-month progression-free survival after initial administration. This case suggests that, as in small cell lung cancer, AMR is effective for SmCCE.
authors.affiliation: Department of Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan. nagasaki@jikei.ac.jp
authors.forename: Eijiro
authors.initials: E
authors.lastname: Nagasaki
authors.forename: Masami
authors.initials: M
authors.lastname: Yuda
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Tanishima
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Arakawa
authors.forename: Kazuma
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Sakuyama
authors.forename: Daisuke
authors.initials: D
authors.lastname: Inoue
authors.forename: Katsunori
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Masao
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Nobuo
authors.initials: N
authors.lastname: Omura
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Keisuke
authors.initials: K
authors.lastname: Aiba
mesh_terms: D018943:Anthracyclines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; C055866:amrubicin